HOMOLOGOUS RECOMBINATION DEFICIENCY TO PREDICT NEOADJUVANT CHEMOTHERAPY NECESSITY IN BLADDER CANCER

摘要

Methods and materials involved in assessing samples (e.g., cancer cells) are provided for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cancer cell (e.g., a bladder cancer cell) contains an HRD signature are provided. Materials and methods for identifying cancer cells (e.g., bladder cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen (e.g., neoadjuvant chemotherapy) also are provided.